United States securities and exchange commission logo





                     August 10, 2023

       Denis Corin
       President, Chief Executive Officer and Director
       Q BioMed Inc.
       c/o Ortoli Rosenstadt LLP
       366 Madison Avenue , 3rd Floor
       New York , NY 10017

                                                        Re: Q BioMed Inc.
                                                            Form 10-K for the
Fiscal Year Ended November 30, 2022
                                                            Filed May 26, 2023
                                                            File No. 000-55535

       Dear Denis Corin:

                We issued comments to you on the above captioned filing on July
3, 2023. As of the date
       of this letter, these comments remain outstanding and unresolved. We
expect you to provide a
       complete, substantive response to these comments by August 25, 2023.

               If you do not respond, we will, consistent with our obligations
under the federal securities
       laws, decide how we will seek to resolve material outstanding comments
and complete our
       review of your filing and your disclosure. Among other things, we may
decide to release
       publicly, through the agency's EDGAR system, all correspondence,
including this letter, relating
       to the review of your filings, consistent with the staff's decision to
publicly release comment and
       response letters relating to disclosure filings it has reviewed.

              Please contact Ibolya Ignat at 202-551-3636 or Angela Connell at
202-551-3426 with any
       questions.




                     Sincerely,


                     Division of Corporation Finance

                     Office of Life Sciences